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j ourna l homepage: www.e lsev ie r .com/ locate /atgOpen access and data sharing: Easier said than doneThis is an interview with Dr. Gholson Lyon, Assistant Professor and
researcher at Cold Spring Harbor Laboratory. Dr. Lyon's work focuses
on understanding the pathophysiological basis of neuropsychiatric con-
ditions, with a long-term goal of expanding access to preventive ser-
vices and treatment for these disorders. Dr. Lyon is also committed to
the open discussion and management of the ethical implications of
human genetics research, along with helping to move whole genome
sequencing into the clinical world. He frequently speaks about the chal-
lenges of integrating genomics into clinical medicine and is vocal about
the need for open access and data sharing and was among the 14,699
academicians who boycotted Elsevier for its restrictions on the dissem-
ination of publications.
1. Open access initiatives have revolutionized knowledge generation
and distribution. Is open access crucial to advancing genomics? Why or
why not?
GL: Open access is a vehicle to democraticizing data because it en-
sures that anyone can get the data. But accessing the data is not useful
unless one can also access reports based on the data.
2. If data are described in a publication, should researchers have ac-
cess also to the actual data set to test the reproducibility of results, or
conduct different analyses?
Yes, deﬁnitely. Currently, the NIH policy and practice are to place
human genome sequencing data and genotyping data into controlled
access databases, such as dbGaP. People say dbGaP is accessible but, in
fact, access to it is impossibly hard. In order to gain access, one must
apply through controlled access data committees. The process of apply-
ing involves formal applications entailing an enormous amount of paper
work, including documentation of ethical assurances and IRB andHIPPA
compliance. Last I checked, you had to be a Principal Investigator (P.I.) in
order to even apply. Even applying as a P.I., I've been rejected because
the committees wanted additional explanations regarding what I
wanted to do with the data. So, in my view the NIH is extraordinarily
conservative about whom they give the data to.http://dx.doi.org/10.1016/j.atg.2014.09.008The access issue points to a problemwith how bureaucrats and eth-
icists work together to develop policy guidance and practice standards.
Both have the best intentions but they end up creating enormous bu-
reaucratic hoops that make it very difﬁcult for anyone to get access to
the data, other than the very few established players. Obtaining access
is easier if you're a researcher working at a major genome sequencing
center with substantial NIH support because there are teams of people
paid to help gain access to these data. But if you'reworking in a small ge-
nomics lab, it's basically a non-starter, because small labs can't afford to
take the time and effort to fulﬁll these requirements, particularly if their
chances of success are low. And the slim chance of success applies to ge-
nomic or genotyping data. Importantly, I think that there are a lot of
younger people who could do breakthrough work if given the opportu-
nity but as unestablished investigators, it's very hard if not impossible
for them to gain access to it. Open access initiatives are intended to de-
mocratize data in just this way, namely permitting novices, as it were,
the opportunity to gain access to data and to use it to advance knowl-
edge. But in practice, access to this data is very limited and we may be
paying a great societal price for these restrictions.
For these reasons, I'm pessimistic in 2014 that there will be near-
term changes to enable truly open sharing of human genomic and phe-
notype data. There seems to bemore of a way forward researching non-
human organisms, such as plants and yeast, because these genomes are
much more openly accessible. Perhaps it will take the next 5 years, or
more, for people to become comfortable with truly open sharing of
human genomic data.
3. The problem you describe is broader if you consider researchers in
less resourced institutions or countries whowould like access to public-
ly funded data. Might there be a solution that would enable you and
others in less resourced institutions to continue to work on human
data?
GL: I think there are established centers like the Broad, Baylor,
WashU St. Louis, and some newly emerging players like theNYGenome
Center, BGI, and MT. Sinai Genomics that have researchers with sub-
stantial resources, in the order of tens to hundreds of millions of dollars,
and so are able to conduct very active projectswhere they're sequencing
tens of thousands to hundreds of thousands of exomes and eventually
whole genomes. And for the most part, I think that right now we're liv-
ing in a very siloedworldwhere certain genomic centers, such as those I
just mentioned, will continue to dominate for the next 5 years. When
the cost of a whole genome is about $100 using small, relatively cheap
sequencing devices, then at that point there might be an inﬂection
where people buy their own sequencing devices and generate and ana-
lyze their owndata and the siloed nature of data generation and analysis
ends. But until we can get a whole genome for around $100 I think the
siloed status quo will continue to prevail. Well-funded research institu-
tions will dominate the ﬁeld, commercial companies will offer more
targeted panels, increasing their revenue, and some academics, such
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isms and thus avoid dealingwith the current bureaucracy governing ac-
cess to human genomic data.
4. This 5-year period you describe would seem to have a signiﬁcant
negative impact on innovation. Are there dire consequences for re-
searchers who can't get access to data or even society at large?
GL: I see very little leadership in America that is working on ways to
engage people to collect and share a large amount of genomic data with
detailed longitudinal phenotypic information. Without public engage-
ment we will not have the data we need to implement genomics into
clinical medicine. While, there's been talk about the Million Veteran
Program, progress has been extremely slow on the uptake. The program
is supposed to collect and sequence a million veterans. A contract was
given to the company Personalis to sequence 1000 of those genomes
but it is not clear whether sequencing is being done in any clinical
grade manner, and there has been little comment by the government
about the status of that project. Also, the NIH recently announced the
delay of the National Children's Study that was supposed to start in
2015. After years of pilot studies, they were ﬁnally going to start
collecting from birth the genomes of 100,000 children along with all
kinds of clinical details. But now political gridlock, lack of funding and
all sorts of other issues give the project an uncertain future. As far as I
can tell, there's no leadership in the US government advocating for the
need to be doing these kinds of big genome sequencing projects. To
me, sequencing a million people in America in a clinical-grade manner
and returning results directly to the donorswould be very helpful to de-
termine whether any mutation has any particular predictive value for
certain phenotypes. There are other countries such as the UK that are
embracing this. They've said that they're going to sequence 100,000
people. BGI in China has been talking about sequencing amillion people.
So other countries are very quicklymoving ahead of America because of
this lack of leadership and funding.
5. There are some sequencing projects underway; the privately
funded PGP, and NIH funded BabySeq. Do you feel that these projects
are unable to make even a small impact?
GL: I'm glad that the BabySeq is underway but it's small relative to a
million people. These projects will make a small impact because of their
small size, but I certainly hope that they scale up soon. Many of these
projects could learn something from the consumer interfaces developed
by companies such as 23andMe and Ancestry.com.
6. Your point about leadership is well taken. Two newly established
global organizationswould seem to be picking up some of this slack you
refer to. The new Global Alliance for Genomic Health is establishing
standards for enabling greater global data sharing and the Genomic
Medicine Alliance aims to identify common strategies for implementing
translational research and removing common delivery system and pol-
icy barriers to adopting genomics based care. Might these initiatives
propel the need for data sharing?
GL: Sharing will happen, although perhaps not as quickly as I might
like. I sometimes go back and read the literature on the Human Genome
Project (HGP) and am reminded of what was happening with the HGP
before Craig Venter announced he was going to undertake shotgun se-
quencing. Right now we have a governmental bureaucracy that's mov-
ing extraordinarily slowly such that maybe in 50 years time we'll have
newborns sequenced on a large scale. What we need are visionaries
like Elon Musk or Steve Jobs with deep pockets who announce that
they're going to sequence whole genomes for a million people in the
next ﬁve years and do it because they have the money and will to
succeed. There are a few companies that have started talking about
such an effort, like Human Longevity, which Craig Venter recentlyannounced, but they haven't gained traction yet. But unless someone
takes the ball and runs with it, I think we're trapped in the status quo.
7. Certainly there would be advantages to this kind of industry
funded initiative but might any industry driven initiative, with proprie-
tary interests, doom guarantees of open access and availability in the
public arena?
GL: That's true, but what I'm saying is that we really need someone
to shake it up and ﬁgure out a way to accelerate the governmental ef-
forts. I think certain key things need to come together; namely public
engagement and technological ease of uploading data. For example,
Apple will be releasing I-health on their new operating system. They're
trying to create a platform where people can upload and integrate all
sorts of mobile health data. I could easily imagine that some people, in-
cluding at Illumina, could easily build on that health platform; get your
sequence, upload it to the platform and share it quickly with others. So,
there's a lot of potential. I'm waiting to see if something develops in the
next year or two that's relatively constructive.
8. Given that data requires human donors and to some extent they
have to consent to third party access, do you think privacy concerns
pose an obstacle to doing a large scale-sequencing project?
GL: I think there will always be a cohort of early adopters, people
who enable open sharing, like the PGP project which is open to anyone
or JonathanWillbanks' portable legal consent that allows people to sign
up and donate data. There are a lot of similar nascent efforts that are be-
ginning to spread. With the right sort of donors or the right people to
back it, a partnership with a disruptive company could make a large
scale sequencing project possible. Yes, there are plenty of people out
there who don't want to share their data, but in America, which has a
population of ~318 million people, I think that you could ﬁnd 1–2 mil-
lion people who, with the right kind of engagement, would participate,
and then such a project could be doable. For example, say you buy an
iPhone, along with a marketing campaign that says donate your DNA
andwe'll put your genome on this applicationwhich allows you to con-
nect upwith other individuals, ﬁnd out variants of interest, upload your
phenotypic data and get back predictions, that could excite 1–2 million
people to donate. It would require Apple teaming up with a company
like 23andMe or a company which is not in the genomic sector but
which has deep pockets and engages millions of people, like Facebook.
I don't know if that will happen in the next 5 years or not, but it certain-
ly will happen when we have a $100 genome. The problem is that cur-
rently, in July 2014, the true cost of awhole genomewith good coverage
is on the order of $1500–3000 and even more than that with good bio-
informatics analysis. So, we are awaiting the development of newer,
cheaper technologies for sequencing and interpretation.
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